Lowest-Rated StocksLowest-RatedNASDAQ:SAGE Sage Therapeutics (SAGE) Stock Price, News & Analysis $7.50 -0.14 (-1.83%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$7.43▼$7.7250-Day Range$7.50▼$13.0852-Week Range$7.43▼$28.26Volume667,173 shsAverage Volume1.05 million shsMarket Capitalization$457.88 millionP/E RatioN/ADividend YieldN/APrice Target$16.06 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Sage Therapeutics alerts: Email Address Sage Therapeutics MarketRank™ Stock AnalysisAnalyst RatingReduce1.95 Rating ScoreUpside/Downside114.1% Upside$16.06 Price TargetShort InterestBearish11.83% of Float Sold ShortDividend StrengthN/ASustainability-1.64Upright™ Environmental ScoreNews Sentiment0.02Based on 16 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($6.39) to ($5.09) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.05 out of 5 starsMedical Sector179th out of 910 stocksPharmaceutical Preparations Industry71st out of 426 stocks 4.0 Analyst's Opinion Consensus RatingSage Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.95, and is based on 1 buy rating, 16 hold ratings, and 2 sell ratings.Amount of Analyst CoverageSage Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Sage Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted11.83% of the float of Sage Therapeutics has been sold short.Short Interest Ratio / Days to CoverSage Therapeutics has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in Sage Therapeutics has recently increased by 7.62%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSage Therapeutics does not currently pay a dividend.Dividend GrowthSage Therapeutics does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSage Therapeutics has received a 61.41% net impact score from Upright. The largest positive contribution comes from its "Mental diseases" impact, which is driven by its "Antidepressants" and "Clinical research services for mental health" products. See details.Environmental SustainabilityThe Environmental Impact score for Sage Therapeutics is -1.64. Previous Next 1.7 News and Social Media Coverage News SentimentSage Therapeutics has a news sentiment score of 0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Sage Therapeutics this week, compared to 5 articles on an average week.Search InterestOnly 1 people have searched for SAGE on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Sage Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sage Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.50% of the stock of Sage Therapeutics is held by insiders.Percentage Held by Institutions99.22% of the stock of Sage Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sage Therapeutics' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Sage Therapeutics are expected to grow in the coming year, from ($6.39) to ($5.09) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sage Therapeutics is -0.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sage Therapeutics is -0.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSage Therapeutics has a P/B Ratio of 0.56. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Sage Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss Ratings“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.Learn these 4 simple steps and protect your savings before it’s too late. About Sage Therapeutics Stock (NASDAQ:SAGE)Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.Read More SAGE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SAGE Stock News HeadlinesSeptember 7 at 12:38 PM | markets.businessinsider.comINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sage TherapeuticsSeptember 7 at 10:07 AM | globenewswire.comSAGE INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Sage Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead CaseSeptember 7, 2024 | Paradigm Press (Ad)Kamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… September 6 at 9:36 PM | msn.comSage Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky LLP for More Information – SAGESeptember 6 at 4:18 PM | globenewswire.comROSEN, GLOBAL INVESTOR COUNSEL, Encourages Sage Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAGESeptember 5 at 4:03 PM | prnewswire.comSAGE INVESTOR ALERT: Edelson Lechtzin LLP Urges Sage Therapeutics, Inc. (NASDAQ: SAGE) Shareholders to Seek Legal Counsel About the Pending Securities Fraud Class ActionSeptember 5 at 4:00 PM | globenewswire.comSAGE SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sage Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!September 5 at 8:30 AM | prnewswire.comSage Therapeutics Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SAGESeptember 7, 2024 | Paradigm Press (Ad)Kamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… September 4 at 6:25 PM | globenewswire.comSAGE Class Action Alert: Robbins LLP Reminds Stockholders of the Sage Therapeutics, Inc. Class ActionSeptember 3, 2024 | tmcnet.comREMINDER - Sage Therapeutics, Inc. Investor Alert: Robbins LLP Reminds Shareholders of the SAGE Class Action LawsuitSeptember 3, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sage Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAGESeptember 3, 2024 | globenewswire.comSAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law FirmSeptember 2, 2024 | prnewswire.comSAGE SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sage Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!September 1, 2024 | businesswire.comRosen Law Firm Urges Sage Therapeutics, Inc. (NASDAQ: SAGE) Stockholders with Large Losses to Contact the Firm for Information About Their RightsSeptember 1, 2024 | markets.businessinsider.comSHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sage TherapeuticsSeptember 1, 2024 | globenewswire.comSAGE INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Sage Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitSeptember 1, 2024 | globenewswire.comROSEN, NATIONAL TRIAL COUNSEL, Encourages Sage Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAGESee More Headlines Receive SAGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sage Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/31/2024Today9/07/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SAGE CUSIPN/A CIK1597553 Webwww.sagerx.com Phone(617) 299-8380Fax617-299-8379Employees690Year FoundedN/APrice Target and Rating Average Stock Price Target$16.06 High Stock Price Target$25.00 Low Stock Price Target$8.00 Potential Upside/Downside+114.1%Consensus RatingReduce Rating Score (0-4)1.95 Research Coverage19 Analysts Profitability EPS (Most Recent Fiscal Year)($8.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-541,490,000.00 Net Margins-458.30% Pretax Margin-458.30% Return on Equity-55.87% Return on Assets-50.00% Debt Debt-to-Equity RatioN/A Current Ratio9.95 Quick Ratio9.95 Sales & Book Value Annual Sales$86.46 million Price / Sales5.30 Cash FlowN/A Price / Cash FlowN/A Book Value$13.32 per share Price / Book0.56Miscellaneous Outstanding Shares61,050,000Free Float56,872,000Market Cap$457.88 million OptionableOptionable Beta0.91 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Barry E. Greene (Age 61)President, CEO & Director Comp: $1.29MMs. Kimi E. Iguchi CPA (Age 62)CFO & Treasurer Comp: $665.37kMs. Anne Marie Cook Esq. (Age 62)Senior VP, General Counsel & Secretary Comp: $711.6kMr. Christopher Benecchi (Age 52)Chief Business Officer Comp: $703.76kDr. Laura Gault M.D.Ph.D., Chief Medical OfficerMr. Matt LasmanisChief Technology & Innovation OfficerMr. Mike QuirkChief Scientific OfficerAshley KaplowitzDirector of Investor RelationsMs. Erin E. Lanciani (Age 55)Chief People & Experience Officer Dr. Amy Schacterle Ph.D.Senior Vice President of R&D Strategy and Business ManagementMore ExecutivesKey CompetitorsEmergent BioSolutionsNYSE:EBSSchrödingerNASDAQ:SDGRRecursion PharmaceuticalsNASDAQ:RXRXMirum PharmaceuticalsNASDAQ:MIRMZai LabNASDAQ:ZLABView All CompetitorsInstitutional OwnershipPoint72 Asset Management L.P.Sold 635,011 shares on 8/19/2024Ownership: 0.010%Algert Global LLCBought 39,114 shares on 8/16/2024Ownership: 0.106%The Manufacturers Life Insurance Company Sold 5,428 shares on 8/15/2024Ownership: 0.141%Dark Forest Capital Management LPBought 22,245 shares on 8/15/2024Ownership: 0.036%Point72 Asia Singapore Pte. Ltd.Bought 21,411 shares on 8/15/2024Ownership: 0.036%View All Institutional Transactions SAGE Stock Analysis - Frequently Asked Questions How have SAGE shares performed this year? Sage Therapeutics' stock was trading at $21.67 on January 1st, 2024. Since then, SAGE shares have decreased by 65.4% and is now trading at $7.50. View the best growth stocks for 2024 here. How were Sage Therapeutics' earnings last quarter? Sage Therapeutics, Inc. (NASDAQ:SAGE) issued its earnings results on Wednesday, July, 31st. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.68) by $0.02. The business's quarterly revenue was up 249.8% on a year-over-year basis. Who are Sage Therapeutics' major shareholders? Top institutional investors of Sage Therapeutics include Federated Hermes Inc. (1.11%), Renaissance Technologies LLC (0.92%), Dimensional Fund Advisors LP (0.85%) and Cubist Systematic Strategies LLC (0.80%). Insiders that own company stock include George Golumbeski and Elizabeth Barrett. View institutional ownership trends. How do I buy shares of Sage Therapeutics? Shares of SAGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Sage Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sage Therapeutics investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD) and Netflix (NFLX). This page (NASDAQ:SAGE) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sage Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sage Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.